Previous studies have shown the β-catenin signaling pathway to promote the development of tolerogenic dendritic cells (DCs) that are capable of driving regulatory T cell (Treg) differentiation. Interestingly, tolerogenic DCs have recently been described to play a role in carcinogenesis. However, the molecular mechanisms underlying the establishment of immune tolerance by this DC population are poorly understood and the methods by which developing
cancers can co-opt this pathway to subvert immune surveillance are unknown. Using a genetically engineered model, we demonstrate that melanoma-derived Wnt5a ligand is a novel regulator of indoleamine 2,3-dioxygenase-1 (IDO) expression in local myeloid DCs and that Wnt5a induces the durable expression and enzymatic activity of IDO via β-catenin (Figures 1,2) . Further, we show that Wnt5a-conditioned DCs promote Treg differentiation in an IDO-dependent manner and that melanoma secretion of Wnt5a both suppresses the generation of anti-tumor immunity and promotes melanoma progression in vivo (Figure 3 ). By genetically silencing the PORCN acyl transferase which is necessary for Wnt ligand secretion, we confirm the role of the soluble Wnt ligands in directing ;Pten lox/lox primary melanomas exhibit increased expression levels of β-catenin target genes, including axin2, ccnd1, c-myc, and tcf-7, based on qrt-PCR relative to BMDCs derived from non-tumor bearing mice. Representative of 2 independent experiments. P value based on a two-way ANOVA. B. DCs isolated from tumor-draining lymph node (TDLN) tissues harvested from melanomabearing Tyr::CreER;Braf CA ;Pten lox/lox mice exhibit elevated expression levels of β-catenin target genes relative to distant LN tissues harvested from the same mice as well as LN tissues harvested from non-tumor-bearing cre -control mice. Representative of 2 independent experiments. P value based on a two-way ANOVA. C. + T lymphocyte populations are increased in PORCN silenced B16/F10 tumors based on flow cytometry. Performed in triplicate. Representative of 2 independent experiments. P value based on two-tailed student's t test. F. Tumor-infiltrating CD8 + T lymphocytes in PORCN silenced B16/F10 tumors exhibit diminished levels of surface PD-1 expression based on flow cytometry. Performed in triplicate. Representative of 2 independent experiments. P value based on two-tailed student's t test.
DC tolerization both in vitro and in vivo while also establishing a potential pharmacologic target for manipulating this novel pathway (Figure 4) . Indeed, utilizing a small molecule inhibitor of PORCN, we are able to reverse Wnt5a-mediated IDO upregulation by DCs both in vitro and in vivo. These findings were expanded in further melanoma studies where we demonstrated small molecule PORCN inhibition to synergistically suppress melanoma progression while also enhancing antimelanoma immunity in the setting of combination anti-CTLA-4 therapy ( Figure 5 ). Additional work in human melanoma confirms the existence of this Wnt5a-mediated paracrine signaling pathway in DCs and reveals by microarray dataset analysis that human melanoma co-expression of Wnt5a and FoxP3 is highly significant. These data prompted us to hypothesize that a Wnt5a-induced gene signature in the melanoma microenvironment may be indicative of immune tolerance. Indeed, we have found that a Wnt5a gene signature identified in purified sentinel lymph node-derived DCs is associated with an inferior clinical prognosis in melanoma patients. This work emphasizes the importance of DC populations in directing tumor immune surveillance and illustrates that the molecular mechanisms involved in DC physiology represent potential targets for pharmacologically enhancing anti-tumor immunity. B16/F10 tumor-bearing mice were administered C59 alone at 5 mg/kg/day by oral gavage, anti-CTLA-4 mAb alone at 100 μg via intra-peritoneal injection every 3 days, or the combination. Control mice (UT, untreated) received daily vehicle control by oral gavage and isotype control antibody every 3 days. 5-6 mice per group. Representative of two independent experiments. B. Inhibition of Wnt secretion enhances the activation of B16/F10 melanoma-infiltrating CD8 + T cells. Tumor-infiltrating 41BB + CD8 + T cells in each treatment group were analyzed by flow cytometry. 4 mice per group. Representative of 2 independent experiments. P value based on a oneway ANOVA. C. Inhibition of Wnt secretion augments anti-CTLA-4 mAb-induced expansion of TRP2-specific CD8 + T cells in B16/F10 melanomas based on dextramer flow cytometry analysis. 4 mice per group. Representative of 2 independent experiments. P value based on a one-way ANOVA.
